{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Encephalopathy&page=3",
    "query": {
      "condition": "Epileptic Encephalopathy",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 64,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Encephalopathy&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Encephalopathy&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T02:03:05.132Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02473445",
      "title": "A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mitochondrial Diseases"
      ],
      "interventions": [
        {
          "name": "Cysteamine Bitartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-05-19",
      "completion_date": "2017-03-06",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Stanford, California • Akron, Ohio + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473445"
    },
    {
      "nct_id": "NCT00006176",
      "title": "Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Familial Dementia With Neuroserpin Inclusion Bodies",
        "Nervous System Heredodegenerative Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2000-08-10",
      "completion_date": "2009-08-04",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006176"
    },
    {
      "nct_id": "NCT06872125",
      "title": "A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "zorevunersen",
          "type": "DRUG"
        },
        {
          "name": "Sham Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stoke Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 170,
      "start_date": "2025-06-04",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06872125"
    },
    {
      "nct_id": "NCT02682927",
      "title": "A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome",
        "Seizure Disorder"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 262,
      "start_date": "2016-01-15",
      "completion_date": "2020-07-29",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682927"
    },
    {
      "nct_id": "NCT03166215",
      "title": "Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Developmental and/or Epileptic Encephalopathies"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-08-17",
      "completion_date": "2018-09-19",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Port Charlotte, Florida • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03166215"
    },
    {
      "nct_id": "NCT05226780",
      "title": "Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-921352",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "2 Years to 22 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-07-12",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05226780"
    },
    {
      "nct_id": "NCT04937062",
      "title": "Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder",
        "Developmental and Epileptic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Months to 17 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-03-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • New York, New York",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04937062"
    },
    {
      "nct_id": "NCT04924153",
      "title": "A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "KCNT1-Related Epilepsy"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2021-08-17",
      "completion_date": "2023-08-29",
      "has_results": false,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04924153"
    },
    {
      "nct_id": "NCT03936777",
      "title": "A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome",
        "Lennox Gastaut Syndrome",
        "Epileptic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 412,
      "start_date": "2019-04-22",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 26,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936777"
    },
    {
      "nct_id": "NCT04873869",
      "title": "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-921352",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-31",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-02T02:03:05.132Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04873869"
    }
  ]
}